







# EudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia

Presented by: Vladimir Raketić, DVM, spec; Audit /QM group

Ministry of Agriculture, Forestry and Water Managment, Veterinary Directorate, Serbia



#### **Objectives**

PhV in Serbia- beginnings
Established system and achieved results
Regulatory PhV requirements
Changes by new legislation
Goals and constraints



#### Republic of Serbia

1993 – Veterinary faculty - Pharmacology Department, (adverse drugs reactions)

2005 – Agency of Medicines and Medical Devices of Serbia (ALIMS)







## Legal basis Serbian PhV System



Law on Medicines and Medical Devices (O.G. 30/10)

Bylaw defining the manner for reporting, collecting data and monitoring adverse reactions of medicinal products (2006 – under revision)

VOLUME 9B (EU) (Directive 2001/82/EC, Regulation EC 726/2004)

Established pharmacovigilance system for the collection and evaluation of information relevant to the risk-benefit balance of medicinal products.




### **EudraVigilance veterinary(EVVet) Definition**

- EudraVigilance is a data processing network and management system for reporting and evaluating suspected adverse reactions during the development and following the marketing autorisation of the medicinal products.
- In EU, from 2008. submission of adverse events by MAH to NCA is only accepted via electronic means.
- A major update of EVVet will be initiated to improve data input, to harmonise it with international standards and to include a tracking system for surveillance.



### Serbian PhV System Roles and Responsibilities



Regulatory authority (ALIMS; Ministry of Agriculture, Forestry and Water Management- Veterinary Directorate)


Marketing Authorization Holder (MAH) - Qualified Person for PharmacoVigilance (QPPV)

Health Care Professionals – HCP(veterinary practitioners)



#### **ALIMS** rools of organisation VET. PhV

ALIMS attend sistem of:
 safety animals;
 safety persons who application vet. medicines
 safety consumers of goods of animal origin
 safety environmental





#### National Pharmacovigilance Centre - NPC


ADRs reporting (database and signal detection, communication, regulatory measures)

Regulatory procedures (authorizations, renewals, variations)



#### **ADRs** reporting








#### **ADRs reporting - HCP**







#### **ADRs reporting - MAH**



Serious case reports from Serbia
Serious unlisted case reports from abroad

NO gateway for electronic reporting of ICSR

EXPEDITED REPORTING (15 days)



#### ESTABLISHMENT OF REGIONAL CENTRES







#### REGULATORY PROCEDURES



#### **Authorizations**

National procedure

Periodic Safety Update Report (PSUR)

By the Law – full documentation: ... *Postmarketing experience*...

Generic drugs?


Risk Management Plan (RMP)

Detailed Description of PhV System





#### **PSUR** cycle





#### **Changes of PSUR Cycle**

The periodicity of PSUR submission may be amended (lower frequency than once every 3 years is not possible) according to IBD/EU-HBD.

http://www.hma.eu/80.html

Part of application for Marketing Authorization; Postauthorization phase - variation type II.



### Regulatory procedures Current practice in Serbia

Expedited ADRs reporting (within 15 days - serious ADRs from Serbia and serious, unexpected ADRs from abroad)

PSUR (assessed during authorization and renewal procedure)

Safety variations

Risk Management Plan (RMP) +/-



### Revised Serbian regulation defines more requirements in accordance with EU

The applicant for a marketing authorization (MAA) is required to provide a detailed description of PhV system (DDPS);

The risk management system which the MAA will introduce, if necessary;

Updates to the information provided in the DDPS should be made as type II variations.



#### PhV Inspection in Serbia – M.A.F.W.M.-Veterinary Directorate

To ensure that MAH comply with pharmacovigilance regulatory obligations.

Routine Inspections;

Targeted Inspections – when triggers are identified, e.g. submission of poor quality or incomplete PSURs, inconsistencies between reports and other information sources...

PhV Systems Inspections

Product-Specific Inspections



### Instead of CONCLUSION

#### **Problems and Challenges**

- To improve reporting (quality of reports and annual rate)
- PhV Inspection development
- Serbia is not part of EU network Work-sharing assessment reports?
- Crisis Management SOP
- Transparency (ALIMS web site)
- NPC capacity limits (need to increase number of staff, rationalize processes, keep going with training, QMS)



#### Challenges in 2010

- Vet PhV was developed with the work programe of the PhVWP and project on work- sharing between NCAs for the assessment of PSURs.
- Further challenges include:
- Finalisation of Volume 9B;
- Development of guidance and concept of Risk management plans for VMP;
- Development of recommendations on the use of data contained in EVVet.



### **THANK YOU** FOR YOUR ATTENTION